White House Announces GLP-1 Drug Agreements

Last week the Trump Administration announced new agreements with drugmakers Eli Lilly and company, Norvo Nordisk to lower prices on certain popular medications, including GLP-1s.

Starting January 2026, TrumpRx will sell Wegovy for $350 per month and Zepbound for about $346 per month directly to patients. Prices will gradually drop to $250 per month over the next two years.

If new oral GLP-1 drugs approved (semaglutide or orforglipron), Eli Lilly and Novo will offer initial doses for $150 per month.

Prices listed in the headlines may vary due to slightly different language used in the press releases issues by the White House vs. the drug manufacturers.

Details around the Direct to consumer (DTC) program are still unfolding. We expect to hear more, including the full list of available products in 2026.

What’s next

The White House said Eli Lilly and Novo have committed to lowering the cost of these drugs for commercial insurers though they didn’t elaborate on the cost differences.

LifeWise Health Plan of Washington will continue to monitor developments and will assess any impact on our customers once the full scope of the policy is confirmed. Our priority is to ensure appropriate access to medications while keeping them affordable and following regulatory requirements.

We’ll share updates as soon as more information is available.